Potential Role of Brain-Derived Neurotrophic Factor in Omega–3 Fatty Acid Supplementation to Prevent Posttraumatic Distress after Accidental Injury: An Open-Label Pilot Study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
the study. The study protocol was reviewed and approved by the institutional review boards and registered at http://clinicaltrials. gov/ as NCT00671489. Of the 15 patients enrolled, 11 completed the 12-week follow-up. Three patients cancelled a visit at the last minute and 1 lost contact after the 4-week follow-up visit. Patients who completed the trial did not significantly differ from those who did not complete the trial in terms of sex, age, vital signs, and injury severity score [11] , Glasgow Coma Scale [12] and peritraumatic distress inventory scores [13] . A total of 7 n–3 PUFA capsules (Kentech Co. Ltd., Japan) containing 1,470 mg docosahexaenoic acid (22: 6 n–3) and 147 mg eicosapentaenoic acid (20: 5 n–3) were administered daily for 12 weeks in an open-label fashion. Trained psychiatrists assessed posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) by structured clinical interviews [14, 15] at weeks 4 and 12. The interrater reliability for diagnosis of PTSD and MDD was reliable, with values of 1.0 and 0.9, respectively [16] . To assess the serum BDNF levels, 7–10 ml of whole blood were obtained in ethylenediaminetetraacetic acid tubes in the emergency room (week 0), and in week 4 and week 12. Serum BDNF levels were measured using the BDNF Emax Immunoassay System Kit (Promega, Madison, Wisc., USA). The difference between serum BDNF levels at weeks 0 and 12 was compared by paired t test. Scatter plots show the association between the changes in serum BDNF levels and posttraumatic distress as determined by the structured interview at weeks 4 and 12. The distress group consisted of those patients who met the criteria for MDD or PTSD during the trial. We then examined the intergroup differences in changes in serum BDNF levels from week 0 to the endpoint at week 12 using the Wilcoxon rank-sum test. All tests were two-sided, and p ! 0.05 was considered statistically significant. During the first 4 weeks after accident, 1 patient met the criteria for PTSD and remained essentially the same at week 12. Another patient met the criteria for MDD at the 4-week follow-up, but symptoms had disappeared at the 12-week follow-up. Overall, serum BDNF levels were significantly elevated from week 0 to week 12 [n = 11; 52.36 ng/ml (SD = 16.69) vs. 79.83 ng/ml (SD = 13.79); p = 0.001), although they were largely unchanged in the distress group ( fig. 1 ). Changes in BDNF levels between weeks 0 and 12 were significantly greater in the nondistressed group than in the distress group (median 33.5 ng/ml, range 8.5–56.0 vs. median 5.4 ng/ml, range 4.4–6.4; p = 0.037). There was no significant association between changes in serum BDNF level and age, sex, injury severity score, vital signs or peritraumatic distress inventory score (data not shown). We confirmed that supplementation with n–3 fatty acids increased serum BDNF levels. As shown in the figure, the changes seen in serum BDNF levels might be associated with reduced posttraumatic distress on follow-up. Although the present study It is known that severity of depression is associated with low levels of erythrocyte omega–3 polyunsaturated fatty acids (n–3 PUFA) [1] and serum brain-derived neurotrophic factor (BDNF) [2] . Dietary n–3 PUFA promote the maturation of neurons and hippocampal neurogenesis in adult rats [3] and have been found to increase the levels of BDNF in rat hippocampus [4, 5] . BDNF exerts various effects on the nervous system, including neuronal outgrowth, differentiation, synaptic connectivity as well as neuronal repair and survival during development and in adulthood [6–8] . These findings indicate that supplementation with n–3 PUFA enhances the effect of BDNF-related synaptic plasticity and neurogenesis. Recently, Kitamura et al. [9] have shown that hippocampal neurogenesis contributes to the clearance of artificially induced fear memory in mice. It is suggested that adult neurogenesis may play a role in the periodic clearance of hippocampal memory traces in contextual fear conditioning. Therefore, we hypothesized that n–3 PUFA-induced neurogenesis occurring early in the transition period might, by increasing BDNF, facilitate the clearance of fear memory and attenuate posttraumatic distress as a consequence. The aims of the present study were to answer the following questions: whether supplementation with n–3 PUFA increases serum levels of BDNF, and whether change in serum BDNF is associated with the alleviation of posttraumatic distress at followup in our pilot trial [10] . From among 122 consecutive patients who were recruited from the intensive care unit of the National Disaster Medical Center within 240 h of accidental injury during a 23-week period, 27 met the inclusion criteria. Of these 27 eligible patients, 15 agreed to and provided prior written informed consent to participate in Received: August 26, 2010 Accepted after revision: November 20, 2010 Published online: June 30, 2011
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication
Chen, B., Dowlatshahi, D., MacQueen, G. M., Wang, J.-F., & Young, L. T. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01083-6 · Cited by 1,164
Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00181-1 · Cited by 1,151 · cited 1×
“and serum brain-derived neurotrophic factor (BDNF) [”
Self-citationWu, A., Ying, Z., & Gomez-Pinilla, F. (2004) · Journal of Neurotrauma · doi:10.1089/neu.2004.21.1457 · Cited by 518
Docosahexaenoic acid promotes neurogenesis in vitro and in vivo
Kawakita, E., Hashimoto, M., & Shido, O. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.01.021 · Cited by 410
Cited by
Lopresti, A. L., Hood, S. D., & Drummond, P. D. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.014 · Cited by 663
Sijbrandij, M., Kleiboer, A., Bisson, J. I., Barbui, C., & Cuijpers, P. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00121-7 · Cited by 136
Complementary and Alternative Therapies for Autism Spectrum Disorder
Brondino, N., Fusar-Poli, L., Rocchetti, M., Provenzani, U., Barale, F., & Politi, P. (2015) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2015/258589 · Cited by 116
Prevention of trauma and stressor-related disorders: A review
Howlett, J. R., & Stein, M. B. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.261 · Cited by 102
Metadata
- Authors
- Matsuoka, Y., Nishi, D., Yonemoto, N., Hamazaki, K., Hamazaki, T., & Hashimoto, K.
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2011
- Volume
- 80
- Issue
- 5
- Pages
- 310-312
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2068774157
- Cited by
- 45
- References
- 4
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential Role of Brain-Derived Neurotrophic Factor in Omega–3 Fatty Acid Supplementation to Prevent Posttraumatic Distress after Accidental Injury: An Open-Label Pilot Study. https://app.cochat.ai/papers/10.1159/000322980
- The paper
- Matsuoka, Y., Nishi, D., Yonemoto, N., Hamazaki, K., Hamazaki, T., & Hashimoto, K. (2011). Potential Role of Brain-Derived Neurotrophic Factor in Omega–3 Fatty Acid Supplementation to Prevent Posttraumatic Distress after Accidental Injury: An Open-Label Pilot Study. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000322980
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.